COSCIENS Biopharma Inc T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc

Bullboard Posts

Comment by plovieon Nov 11, 2007 10:07am

188 Views

Post# 13789398

RE: Dilution H1 2008

Better do you homework, now we know why your not an analyst. Selling of Canadian HeadQuarters Selling of Reagants business Selling of Impavido 38 million $ in cash at year end. higher than expected due to strong Canadian $ versus US $. - Real-Estate put for sales. At 7mln$ in financial statements - Milestone payment from Keryx to be expected (total deal was 18mln$ for milestone payment - 6mln $ already received in the past) Discussion with partner for Cetroreliw are ongoing on. Feedback is positive. Deal expected in 12 to 24 months. They go for a a "Benchmark deal" (milestones, royalties, reimbursement of R&D)

Bullboard Posts

This battery metals stock is on a path to the global stage